Psychedelic-assisted therapy – Page 2

Rediscovering Psilocybin as an Antidepressive Treatment Strategy

mycolabadmin

Scientists have renewed their investigation into psilocybin, a compound found in certain mushrooms, as a potential treatment for depression. Studies show promising results with patients experiencing significant improvements in depressive symptoms, sometimes sustained for months after a single treatment session. When administered in controlled therapeutic environments with professional support, psilocybin appears relatively safe, though it can cause temporary side effects like headaches and anxiety. This research represents an important shift in how we might treat severe depression, especially in patients who haven’t responded to conventional antidepressants.

Patient perspectives and experiences with psilocybin treatment for treatment-resistant depression: a qualitative study

mycolabadmin

This study explored how patients with severe depression that didn’t respond to typical treatments experienced psilocybin therapy. Researchers interviewed 11 patients about their experiences and found that building trust with therapists, managing expectations, and having multiple treatment sessions were crucial. Many patients found the experience intense and overwhelming, and most wanted ongoing support to understand what they experienced and how it affected their recovery.

From Efficacy to Effectiveness: Evaluating Psychedelic Randomized Controlled Trials for Trustworthy Evidence-Based Policy and Practice

mycolabadmin

This paper discusses why testing psychedelic therapies in clinical trials is more complicated than testing regular drugs. When people take psychedelics like MDMA or psilocybin, they clearly notice the effects, which makes it hard to keep the study ‘blinded’ (where neither patients nor researchers know who got the real drug). The author argues that for therapies combining drugs with counseling, this actually makes sense because the therapy itself is part of how the treatment works, not just a confounding factor. However, for stand-alone drug use, this unblinding is a real problem that makes it unclear whether the drug or people’s expectations caused the improvement.

Group psychedelic therapy: empirical estimates of cost-savings and improved access

mycolabadmin

This study examines whether treating multiple patients together in psychedelic-assisted therapy sessions could reduce costs and help more people access these promising psychiatric treatments. Researchers compared group versus individual therapy using MDMA for PTSD and psilocybin for depression, finding that group therapy saved about 35-51% on clinician costs. If adopted widely, group therapy could reduce the number of clinicians needed and potentially save billions of dollars while helping thousands more patients receive treatment.

Ketanserin Reverses the Acute Response to LSD in a Randomized, Double-Blind, Placebo-Controlled, Crossover Study in Healthy Participants

mycolabadmin

Researchers tested whether ketanserin, a drug that blocks serotonin receptors, could stop or reverse an LSD experience once it had already started. In a controlled study with healthy volunteers, ketanserin given one hour after LSD administration cut the duration of the LSD experience from 8.5 hours down to 3.5 hours and eliminated visual and auditory hallucinations. This finding suggests ketanserin could be useful as an emergency medication in psychedelic-assisted therapy to help patients who have negative reactions to LSD.

Identification of Blood Biomarkers of Psilocybin-Assisted Therapy Treatment Response for Generalised Anxiety Disorder

mycolabadmin

Researchers studied how psilocybin-assisted therapy works for people with anxiety disorders by examining blood samples from patients who responded well to treatment versus those who didn’t. They identified four genes whose expression patterns could help predict which anxiety patients would benefit from psilocybin therapy before starting treatment. This breakthrough could help doctors avoid giving intensive treatment to patients unlikely to respond and instead direct them toward more effective alternatives.

Acute and Chronic Psilocybin in Mouse Models of Psychiatric Disorders

mycolabadmin

Researchers tested psilocybin (the active compound in magic mushrooms) in mice bred to show obsessive-compulsive behaviors. A single dose of psilocybin reduced compulsive grooming for about a week, but giving it repeatedly over time did not help with anxiety, depression, or compulsive behaviors. The findings suggest psilocybin might work best as a one-time treatment rather than repeated doses, which has implications for how these drugs might be used in future psychiatric treatment.

Expanded access to psychedelic treatments: comparing American and Canadian policies

mycolabadmin

This article compares how the United States and Canada allow patients with serious health conditions like PTSD and depression to access experimental psychedelic treatments outside of clinical trials. Canada’s program has allowed over 200 patients to access psilocybin and MDMA treatments since 2022, while the US has only approved 50 patients for MDMA. The authors argue that Canada’s approach is more ethical and accessible, and suggest the US should streamline its process to help more patients who have failed conventional treatments.

Ethical Considerations Regarding Psychedelics for Clinical Pain Research

mycolabadmin

This paper examines the ethical considerations necessary when conducting research on psychedelics like psilocybin for treating chronic pain. With chronic pain affecting millions of Americans and traditional treatments like opioids causing significant problems, researchers are exploring psychedelics as alternatives. The authors provide guidance on obtaining proper informed consent, protecting vulnerable patients, managing regulatory requirements, and ensuring research benefits participants while following four key ethical principles: autonomy, beneficence, justice, and avoiding harm.

Exploring psychedelic use in athletes and their attitudes toward psilocybin-assisted therapy in concussion recovery

mycolabadmin

This study surveyed athletes and sports staff in Canada and the United States about their views on using psilocybin-assisted therapy to treat concussion symptoms. Researchers found that about 36% of athletes had used psychedelics in the past year, with psilocybin being the most common. Most athletes (61%) and staff (71%) said they would be willing to try or support psilocybin therapy for concussion recovery if research showed it was beneficial. The main factor influencing willingness was knowledge about psilocybin and positive attitudes toward it.

Research Topic: Psychedelic-assisted therapy